Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow MNCs in Ebstein Anomaly Repair
NCT02914171Phase 1Completed
- Start
- Sep 2016
- Primary completion
- Mar 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous bone marrow-derived mononuclear cell in Ebstein anomaly (EA) (2 arms). Primary endpoints: Number of adverse events at 24 months, Severity of adverse events at 24 months and 16 more. Started Sep 2016; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
Ebstein anomaly (EA)
Beyond the preview
Go deeper on NCT02914171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914171.